First iPS Cell Trial Underway But A Long Way To Go
This article was originally published in PharmAsia News
Executive Summary
Researchers in Japan have "dosed" the initial patient in the world's first clinical trial involving a regenerative therapy based on the country's flagship induced pluripotent stem (iPS) cell technology.
You may also be interested in...
Global First As Japan Starts iPS Cell Trial In Parkinson's
Building on its national expertise in the area, Japan is starting the first clinical trial globally to assess the use of iPS-derived cells for the treatment of Parkinson’s disease.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: another big deal in radiopharmaceuticals; BioNTech’s ADC pipeline; China CDMOs embrace uncertain future; at look at the rivals in MASH; and industry views on how AI might be transformative.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Galderma prepares to take on Dupixent; Pfizer’s plans for Adcetris in DLBCL; Lilly’s donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS’s CDTO Greg Meyers.